Related Experiment Video
Updated: Jun 17, 2026
Identifying the Binding Proteins of Small Ligands with the Differential Radial Capillary Action of Ligand Assay (DRaCALA)
Published on: March 19, 2021
Discovery and characterization of [3H]8-OH-DPAT binding to HeLaS3 cells
Jin-Jye Feng1, Fong-Chi Cheng, Chun-Hsiung Lin
1Institute of Molecular and Cellular Biology, National Tsing Hua University, 101 Section 2 Kuang-Fu Road, Hsinchu 30013, Taiwan, ROC. jin-jye.feng@mdsinc.com
Abstract:
Some G protein-coupled receptors (GPCRs) have functional links to cancer biology, yet the manifestation of GPCRs in tumor types is little studied to date. Using a battery of radioligand binding assays, we sought to characterize GPCR recognition binding sites on HeLaS3 tumor cells. High levels of binding of the selective serotonin 5-HT(1A) receptor agonist [3H]8-OH-DPAT were observed in these cells. Saturation and homologous competition experiments indicated that [3H]8-OH-DPAT bound different populations of high- and low-affinity sites. In competition experiments, several serotonergic compounds displaced [3H]8-OH-DPAT binding with low potency from its high-affinity binding sites, suggesting that low-affinity binding is the predominant mode of binding. A variety of drugs targeting different classes of receptors did not affect [3H]8-OH-DPAT binding. These observations may help elucidate the pathophysiological and functional relevance of 5-HT receptors in tumor cells and link GPCRs and tumorigenic mechanisms to pharmacological and chemotherapeutic paradigms.
Insights
This study investigated G protein-coupled receptors (GPCRs) in cancer cells, finding specific serotonin 5-HT(1A) receptors on HeLaS3 tumor cells. These findings link GPCRs to cancer mechanisms and potential drug targets.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- G protein-coupled receptors (GPCRs) are implicated in cancer biology.
- The expression and function of GPCRs in various tumor types remain underexplored.
- Understanding GPCRs in tumors could reveal new therapeutic strategies.
Purpose of the Study:
- To characterize G protein-coupled receptor (GPCR) recognition binding sites on HeLaS3 tumor cells.
- To investigate the binding affinity and specificity of ligands for GPCRs in a cancer cell line.
- To explore the potential relevance of GPCRs in tumorigenesis and cancer therapy.
Main Methods:
- Radioligand binding assays were employed to study GPCRs.
- The selective serotonin 5-HT(1A) receptor agonist [3H]8-OH-DPAT was used.
- Saturation, homologous competition, and heterologous competition experiments were conducted.
Main Results:
- High levels of [3H]8-OH-DPAT binding were observed on HeLaS3 tumor cells.
- [3H]8-OH-DPAT bound to both high- and low-affinity sites.
- Serotonergic compounds showed low potency in displacing binding, indicating low-affinity binding predominance. Other receptor-targeting drugs did not affect binding.
Conclusions:
- The study identified specific serotonin 5-HT(1A) receptor binding on HeLaS3 tumor cells.
- Low-affinity binding appears to be the primary interaction mode for [3H]8-OH-DPAT.
- These findings contribute to understanding the role of GPCRs in tumor pathophysiology and may inform pharmacological and chemotherapeutic approaches.
